Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center

Annals of Hematology

Volumn 95, Issue 6, 2016, Pages 901-909

  Li, Xiao Mei ^a   Rui, Hao Chen ^a   Liang, Dan Dan ^a   Xu, Feng ^a   Liang, Shao Shan ^a   Zhu, Xiao Dong ^a   Huang, Xiang Hua ^a   Liu, Zhi Hong ^a   Zeng, Cai Hong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Chinese population; Clinicopathological characteristics; Light chain deposition disease; Prognostic factors

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C3; CREATININE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PARAPROTEIN; PREDNISOLONE; RETINOL BINDING PROTEIN; THALIDOMIDE; VINCRISTINE; IMMUNOGLOBULIN LIGHT CHAIN;

ADULT; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHINESE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; ELECTROPHORESIS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; HYPERTENSION; HYPOCOMPLEMENTEMIA; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; LIGHT CHAIN DEPOSITION DISEASE; MALE; MEDICAL RECORD REVIEW; MICROSCOPY; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROSCLEROSIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; SURVIVAL; TREATMENT OUTCOME; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY; DIABETIC NEPHROPATHIES; KIDNEY; PATHOLOGY; RETROSPECTIVE STUDY;

ASIAN CONTINENTAL ANCESTRY GROUP; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84964047893     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-016-2659-1     Document Type: Article

References (25)

1. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ (1976) Manifestations of systemic light chain deposition. Am J Med 60:293–299
2. Nasr SH, Valeri AM, Cornell LD, Fidler ME, Sethi S, D’Agati VD, Leung N (2012) Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 7:231–239
3. Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F (2003) Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 42:1154–1163
4. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D’Agati VD (2001) Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12:1482–1492
5. Buxbaum JN, Chuba JV, Hellman GC, Solomon A, Gallo GR (1990) Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 112:455–464
6. Zand L, Nasr SH, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Kumar S, Kyle RA, Fervenza FC, Sethi S, Dingli D, Rajkumar SV, Kapoor P, McCurdy A, Leung N (2015) Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both. Leuk Lymphoma 12:1–8
7. International Myeloma Working G (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121:749–757
8. Ronco P, Plaisier E, Mougenot B, Aucouturier P (2006) Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol 1:1342–1350
9. Soma J, Sato K, Sakuma T, Saito H, Sato H, Sato T, Abbas X, Aucouturier P (2004) Immunoglobulin gamma 3-heavy-chain deposition disease: report of a case and relationship with hypocomplementemia. Am J Kidney Dis 43:13
10. McCaughan JA, O’Rourke DM, Courtney AE (2013) The complement cascade in kidney disease: from sideline to center stage. Am J Kidney Dis 62:604–614
11. Nakano T, Matsui M, Inoue I, Awata T, Katayama S, Murakoshi T (2011) Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta 412:843–849
12. Sethi S, Rajkumar SV (2013) Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc 88:1284–1293
13. Masai R, Wakui H, Togashi M, Maki N, Ohtani H, Komatsuda A, Sawada K (2009) Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol 71:9–20
14. Gokden N, Barlogie B, Liapis H (2008) Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 32:17–24
15. Strom EH, Fogazzi GB, Banfi G, Pozzi C, Mihatsch MJ (1994) Light chain deposition disease of the kidney. Morphological aspects in 24 patients. Virchows Arch 425:271–280
16. Herrera GA, Sanders PW, Reddy BV, Hasbargen JA, Hammond WS, Brooke JD (1994) Ultrastructural immunolabeling: a unique diagnostic tool in monoclonal light chain-related renal diseases. Ultrastruct Pathol 18:401–416
17. Herrera GA (1994) Light chain deposition disease (nodular glomerulopathy, kappa light chain deposition disease): a case report. Ultrastruct Pathol 18:119–126
18. Cohen C, Royer B, Javaugue V, Szalat R, El Karoui K, Caulier A, Knebelmann B, Jaccard A, Chevret S, Touchard G, Fermand JP, Arnulf B, Bridoux F (2015) Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88:1135–1143
19. Hassoun H, Flombaum C, D’Agati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL (2008) High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 42:405–412
20. Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N (2008) Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 23:2052–2057
21. Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA (2009) Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94:300–302
22. Corso A, Serricchio G, Zappasodi P, Klersy C, Bosoni T, Moratti R, Castagnola C, Lazzarino M, Pagnucco G, Bernasconi C (1999) Assessment of renal function in patients with multiple myeloma: the role of urinary proteins. Ann Hematol 78:371–375
23. Corso A, Zappasodi P, Pascutto C, Bosoni T, Mangiacavalli S, Lorenzi A, Rusconi C, Lazzarino M (2003) Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications. Ann Hematol 82:487–491
24. Madalena L, Facio ML, Angerosa M, Pandolfo M, Bresciani P, Alejandre M, Pizzolato M, Toblli JE (2007) Urinary excretion of low molecular weight proteins in patients with pure monoclonal light chain proteinuria. J Nephrol 20:683–688
25. Sayed RH, Wechalekar AD, Gilbertson JA, Bass P, Mahmood S, Sachchithanantham S, Fontana M, Patel K, Whelan CJ, Lachmann HJ, Hawkins PN, Gillmore JD (2015) Natural history and outcome of light chain deposition disease. Blood. doi:10.1182/blood-2015-07-658872